Prostat Cancer and Obesity

Abstract

Introduction: Obesity and aggressive prostate cancer are two important clinical conditions because of the prevalence and obesity increases the aggressiveness of prostate cancer. In this study, our aim was to investigate obesity rates at the time of diagnosis in patients who underwent Ga-68 PSMA PET/CT. Materials and methods: 104 patients with newly diagnosed prostate cancer who underwent Ga-68 PSMA PET/CT between 2021 and 2022 for staging were included in this study. The patients' height and weight, pathology results and PSA values, which were recorded routinely before PET/CT, were obtained from Nuclear Medicine patient files. The formula [mass (kg) / height2 (m)] was used to calculate the body mass index (BMI). According to the PSA values and Gleason score of the patients, intermediate and high-risk patients were included in the study. Results: The median age of the patients was 70.5 (range:40-87 yrs) at the time of diagnosis and 67 (64.4 %) patients had metastases at the time of diagnosis. Of the patients, 15 (14.4%) were in the intermediate risk group and 89 (85.6%) were in the high risk group. Of the patients, 33 (31.7%) were normal weight, 45 (43.3%) were overweight, and 26 (25%) were obese. There was no significant difference between prostate cancer risk groups and BMI (p=0.126) Conclusion: As a result, the weight of the majority of the patients in our study was above normal. However, there was no significant difference between overweight and obese and prostate cancer risk groups. However, considering all the literature information, being overweight increases the risk of cancer, and attention should be paid to dietary habits.